I'm sure there were shorts from $120, maybe a few decided that $57 was a better exit than $30?
Early acknowledgement of Auvelity possibly being "blockbuster"?
05's multiple indications starting to hit home?
07's multiple indications?
12?
14?
Buyout offers starting to look legitimate?
Leaks?
Could be any/all of the above.
I honestly don't think $10 billion is a fair buyout offer at this stage and I'm hoping the board would work for shareholders, but that doesn't always seem to be the case.
$20 billion today or $50 billion a year from now. At a glance that sounds completely ridiculous, but I think it's not out of the question.
Recent AXSM News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/11/2024 08:31:50 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/11/2024 08:30:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/05/2024 11:38:42 AM
- Axsome Therapeutics Settles Sunosi® (solriamfetol) Patent Litigation with Unichem Laboratories • GlobeNewswire Inc. • 06/05/2024 11:35:00 AM
- Axsome Therapeutics Joins the American Migraine Foundation to Highlight Unmet Treatment Needs During Migraine & Headache Awareness Month • GlobeNewswire Inc. • 06/04/2024 11:00:00 AM
- Axsome Therapeutics Supports Alzheimer’s & Brain Awareness Month • GlobeNewswire Inc. • 06/03/2024 11:00:00 AM
- Axsome Therapeutics to Participate in Upcoming Investor Conferences • GlobeNewswire Inc. • 05/30/2024 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/30/2024 12:12:56 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/30/2024 12:11:32 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/29/2024 08:24:17 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/29/2024 08:23:38 PM
- Axsome Therapeutics Highlights Data on Solriamfetol Demonstrating Improvement in Cognitive Function in Patients with Obstructive Sleep Apnea or Narcolepsy at SLEEP 2024 • GlobeNewswire Inc. • 05/29/2024 11:00:00 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/28/2024 08:28:52 PM
- Axsome Therapeutics Presents Data from Multiple Programs at the 2024 American Society of Clinical Psychopharmacology Annual (ASCP) Meeting • GlobeNewswire Inc. • 05/28/2024 11:00:00 AM
- Axsome Therapeutics to Present at Upcoming Investor Conferences • GlobeNewswire Inc. • 05/08/2024 11:00:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/06/2024 09:20:33 PM
- Index Futures Point to Strong Monday Opening, Building on Last Week’s Gains; Oil Prices Rise • IH Market News • 05/06/2024 12:09:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2024 11:05:31 AM
- Axsome Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update • GlobeNewswire Inc. • 05/06/2024 11:00:00 AM
- Axsome Therapeutics Recognizes May as Mental Health Awareness Month • GlobeNewswire Inc. • 05/01/2024 11:00:00 AM
- Axsome Therapeutics Highlights Innovative Neuroscience Portfolio at the American Academy of Neurology (AAN) 2024 Annual Meeting • GlobeNewswire Inc. • 04/15/2024 11:00:00 AM
- Axsome Therapeutics to Report First Quarter 2024 Financial Results on May 6 • GlobeNewswire Inc. • 04/10/2024 11:00:00 AM
- Axsome Therapeutics Initiates ENGAGE Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating Disorder • GlobeNewswire Inc. • 04/01/2024 11:00:00 AM
- Axsome Therapeutics Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 Patients • GlobeNewswire Inc. • 03/25/2024 11:00:00 AM
- Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in the SYMPHONY Phase 3 Trial in Narcolepsy • GlobeNewswire Inc. • 03/25/2024 10:30:00 AM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM